The genomic landscape of juvenile myelomonocytic leukemia by Stieglitz, Elliot et al.
The Genomic Landscape of Juvenile Myelomonocytic Leukemia
Elliot Stieglitz#1, Amaro N. Taylor-Weiner#2, Tiffany Y. Chang1, Laura C. Gelston1, Yong-
Dong Wang3, Tali Mazor4, Emilio Esquivel1, Ariel Yu1, Sara Seepo2, Scott Olsen5, Mara 
Rosenberg2, Sophie L. Archambeault1, Ghada Abusin6, Kyle Beckman1, Patrick A. Brown7, 
Michael Briones8, Benjamin Carcamo9, Todd Cooper10, Gary V. Dahl11, Peter D. Emanuel12, 
Mark N. Fluchel13, Rakesh K. Goyal14, Robert J. Hayashi15, Johann Hitzler16, Christopher 
Hugge17, Y. Lucy Liu12, Yoav H. Messinger18, Donald H. Mahoney Jr19, Philip 
Monteleone20, Eneida R. Nemecek21, Philip A. Roehrs22, Reuven J. Schore23, Kimo C. 
Stine24, Clifford M. Takemoto7, Jeffrey A. Toretsky25,26, Joseph F. Costello4, Adam B. 
Olshen27,28, Chip Stewart2, Yongjin Li3, Jing Ma29, Robert B. Gerbing30, Todd A. Alonzo31, 
Gad Getz2,32,33, Tanja Gruber29,34, Todd Golub2,35,36, Kimberly Stegmaier2,35,36, and 
Mignon L. Loh1,37
1Department of Pediatrics, Benioff Children's Hospital, University of California, San Francisco, 
San Francisco, CA
2Broad Institute of MIT and Harvard, Cambridge, MA
3Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN
4Department of Neurological Surgery, University of California, San Francisco, CA
5Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children's Research Hospital, 
Memphis, TN
6Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa 
City, IA
7Department of Pediatrics, The Johns Hopkins Hospital, Baltimore, MA
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Corresponding Authors: Elliot Stieglitz and Mignon Loh. Loh Laboratory, Helen Diller Family Comprehensive Cancer Center, Box 
3112 1450 3rd Street, Room 230 San Francisco, CA 94158 Tel: (415) 514-0853 Fax: (415) 502-5127. E.S. (elliot.stieglitz@ucsf.edu) 
and M.L.L (mignon.loh@ucsf.edu).. 
Author Contributions
E.S., L.C.G, T.M., E.E., A.Y., K.B., and S.L.A. performed the experiments. E.S., A.T.-W., Y.D.W., T.M., M.R., A.B.O., Y.L., J.M., 
R.B.G., and T.A.A. performed data analysis. G.A., M.B., B.C., T.C., G.V.D., P.D.E., M.N.F., R.K.G., R.J.H., J.H., C.H., Y.L.L., 
Y.H.M., D.H.M., E.R.N., P.A.R., R.J.S., K.C.S., C.M.T., J.T., contributed reagents, materials and analysis tools. E.S., A.T.-W., and 
M.L.L. wrote the first draft of the manuscript. T.Y.C. performed statistical analysis. J.F.C., C.S., G.G., T.A.G., T.R.G., K.S., M.L.L. 
supervised research. S.S., and S.R.O managed the project. All coauthors contributed to the final version of the manuscript.
Competing Financial Interests
The authors declare no competing financial interests.
URLs.
Exome Aggregation Consortium (ExAC), http://exac.broadinstitute.org; DesingStudio, http://desgnstudio.illumina.com.
Accession codes.




Nat Genet. Author manuscript; available in PMC 2016 May 01.
Published in final edited form as:













8Department of Pediatrics, Emory University School of Medicine, Aflac Cancer and Blood 
Disorder Center, Atlanta, GA
9Department of Pediatrics, Texas Tech University, El Paso, TX
10Department of Pediatrics, Seattle Children's Hospital, Seattle, WA
11Department of Pediatrics, Stanford School of Medicine, Stanford, CA
12Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little 
Rock, AR
13Department of Pediatric Hematology Oncology, University of Utah, Salt Lake City, UT
14Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
15Department of Pediatrics, Washington University School of Medicine, St. Louis, MO
16Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada
17Pediatric Hematology Oncology, SSM Cardinal Glennon Children's Medical Center, Saint Louis, 
MO
18Division of Pediatric Hematology Oncology, Children's Hospitals and Clinics of Minnesota, 
Minneapolis, MN
19Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX
20Pediatric Hematology Oncology, Pediatric Specialists of Lehigh Valley Hospital, Bethlehem, PA
21Pediatric Bone Marrow Transplant Program, Oregon Health & Science University, Portland, OR
22Department of Pediatrics, University of North Carolina at Chapel Hill, NC
23Division of Pediatric Oncology, Children's National Medical Center, Washington, DC
24Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR
25Department of Pediatrics, Georgetown University, Washington, DC
26Department of Oncology, Georgetown University, Washington, DC
27Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
28Department of Epidemiology and Biostatistics, University of California, San Francisco, CA
29Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
30Department of Statistics, Children's Oncology Group, Monrovia, CA
31Keck School of Medicine, University of Southern California, Los Angeles, CA
32Harvard Medical School, Boston, MA
33Department of Pathology and Cancer Center, Massachusetts General Hospital, Boston, MA
34Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
35Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
Stieglitz et al. Page 2













36Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, 
Boston, MA
37Department of Pediatrics, Benioff Children's Hospital, Helen Diller Family Comprehensive 
Cancer Center, University of California, San Francisco, San Francisco, CA
# These authors contributed equally to this work.
Abstract
Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative neoplasm (MPN) of 
childhood with a poor prognosis. Mutations in NF1, NRAS, KRAS, PTPN11 and CBL occur in 
85% of patients, yet there are currently no risk stratification algorithms capable of predicting 
which patients will be refractory to conventional treatment and therefore be candidates for 
experimental therapies. In addition, there have been few other molecular pathways identified aside 
from the Ras/MAPK pathway to serve as the basis for such novel therapeutic strategies. We 
therefore sought to genomically characterize serial samples from patients at diagnosis through 
relapse and transformation to acute myeloid leukemia in order to expand our knowledge of the 
mutational spectrum in JMML. We identified recurrent mutations in genes involved in signal 
transduction, gene splicing, the polycomb repressive complex 2 (PRC2) and transcription. 
Importantly, the number of somatic alterations present at diagnosis appears to be the major 
determinant of outcome.
INTRODUCTION
Juvenile myelomonocytic leukemia (JMML) is a rare but aggressive form of childhood 
leukemia that exhibits both myelodysplastic and myeloproliferative properties1. The only 
curative therapy is hematopoietic stem cell transplant (HSCT)2. However, some patients 
exhibit highly aggressive disease despite HSCT, while spontaneous remissions are 
occasionally observed in others with minimal therapy3,4. The lack of current laboratory, 
genetic, and clinical features to distinguish these patients5,6 presents a clinical dilemma for 
physicians and parents. We hypothesized that complete genomic characterization of JMML 
would aid in distinguishing these cases and further identify relevant molecular targets for the 
development of novel therapies in patients with the most aggressive disease phenotypes.
Mutations in NF1, NRAS, KRAS, PTPN11 and CBL (“Ras pathway”) currently allow for a 
molecular diagnosis in 85% of patients7-11. Recently, secondary mutations in SETBP1 and 
JAK3 were identified by whole exome sequencing in a small number of patients with JMML 
at diagnosis12. We subsequently identified several patients who had an increase in allele 
frequency of SETBP1 mutations at relapse. We then harnessed droplet digital (dd) PCR to 
show that subclonal SETBP1 mutations were present in nearly a third of patients with 
JMML at diagnosis and independently predicted relapse13. These findings indicated a level 
of genetic complexity previously unrecognized in JMML, and given the limited numbers of 
patients with non-syndromic, de novo JMML who have had exome sequencing performed, 
we set out to assess the genomic landscape of JMML.
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We sequenced samples from patients (n=29) with matched tumor/normal pairs. Seven of 
these patients also had serially acquired relapse and/or transformation to AML samples 
available for sequencing. We then validated our findings in an independent cohort of 71 
patients (Supplementary Figure 1), of whom nine had paired diagnostic-relapse samples 
available. Two of the 29 patients that had exome sequencing were suspected of having 
Noonan syndrome. Upon confirmation, they were removed from all outcome analyses which 
were specific to somatically mutated JMML.
RESULTS
Sequencing of JMML samples using optimized algorithms
We performed whole exome sequencing (WES) at a mean coverage of 95x (Supplementary 
Table 1) on 22 patients with paired germline-diagnosis samples and an additional seven 
patients with germline-diagnosis-relapse samples (Figure 1). Due to the frequent 
contribution of germline mutations in the development of JMML7,11, we optimized an 
algorithm to detect tumor in normal content (deTiN) to retrieve mutations that would 
otherwise have been missed using a traditional tumor-normal bioinformatics approach. Four 
tissue types of germline material were used to serve as normal controls, including buccal 
cells, cord blood, Epstein Barr virus (EBV) immortalized lymphoblasts, and fibroblasts. 
However, by comparing several intra-patient germline sources that contained varying 
degrees of tumor content, it became evident that each tissue type had different amounts of 
tumor contamination in the normal. For example, in patient UPN2026, we first detected a 
heterozygous mutation in RRAS2 from a buccal swab but repeat sequencing of EBV 
immortalized B cells was wild type (Supplementary Figure 2). We therefore implemented 
deTiN, to both assess and correct for the purity of each germline source.
In total, we identified 10 genes that were mutated outside of the previously documented five 
Ras pathway lesions (Supplementary Table 2). These mutations occurred in known 
oncogenes and tumor suppressors that broadly fell into categories of genes affecting the Ras 
pathway, signal transduction, transcription factors, epigenetic regulation, and the 
spliceosome complex (Figure 1 and Table 1).
We next carried out targeted deep sequencing (mean coverage 1380X) on 71 diagnostic 
tumors as well as nine patients who had diagnostic/relapse pairs for the 15 genes identified 
from exome sequencing in order to determine the frequency of these mutations. In addition, 
we sequenced JAK3 as prior reports had identified recurrent subclonal mutations in some 
patients. We also included eleven patients from the discovery cohort in the resequencing 
cohort for validation purposes. All pathogenic mutations identified from exome sequencing 
were identified by targeted resequencing. Recurrent mutations were detected in 14 of the 15 
genes, excluding RRAS2 which was only identified in the discovery cohort (Supplementary 
Table 3). The incidence of mutations in these genes is presented for a total of 100 patients, 
of whom 29 were in the discovery cohort and 71 in the validation cohort (Supplementary 
Figure 3). RNA-sequencing (RNA-seq) data was available in 14 patients (15 samples), and 
confirmed that each of the pathogenic variants detected on exome and deep sequencing were 
transcribed and detected in the RNA (Supplementary Table 4).
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Somatic copy number alterations
The most common karyotypic abnormality identified in WES was deletion of one copy of 
chromosome 7, which occurred in 5 of the exome cases (Supplementary Figure 4). One 
patient with a t(11;17) detected on diagnostic cytogenetics had additional evidence of 
disruption of the NF1 locus on fluorescent in-situ hybridization (data not shown), and was 
found to have a germline mutation in WES. The NF1 c.2041C>T allele had a fractional 
abundance of 33% in RNA transcriptome sequencing (15/45 reads). However, RNA-seq 
failed to identify a fusion RNA in this patient, suggesting that the translocation breakpoints 
might be intergenic. RNA-seq in 14 additional patients did not reveal any structural 
rearrangements resulting in chimeric transcripts. Consistent with previous reports14,15 the 
only additional recurrent structural variants were copy neutral isodisomy at 11q23.3 and 
17q11.2 where CBL and NF1 are located, respectively (Supplementary Figure 5).
Expanding the spectrum of Ras pathway mutations
In addition to canonical NF1, KRAS, NRAS, PTPN11 and CBL alterations, we identified a 
previously described RRAS mutation in one patient16, as well as an RRAS2 alteration in 
another patient, neither of which harbored other driver mutations at diagnosis. Mutations in 
RRAS2, a member of the Ras GTPase superfamily encoding the TC21 oncoprotein, have 
previously been limited to solid malignancies including ovarian, endometrial and squamous 
cell carcinomas17 and regulate TGFβ signaling through the loss of NF118. The RRAS2 point 
mutation in our patient results in the p.Q72L amino acid substitution that was previously 
shown to confer transformative properties as evidenced by increased colony formation in 
vitro and increased tumorgenicity after inoculation in mice compared to wild type RRAS219.
While Ras pathway lesions have traditionally been thought to represent largely mutually 
exclusive events20, co-existing mutations in NRAS, KRAS, PTPN11, CBL, and NF1 were 
found in 11/100 (11.0%) of patients (Figure 2). Analysis of single colonies for two patients 
with compound Ras pathway mutations indicate that both mutations occurred in the same 
colony (Supplementary Table 5). PTPN11 and NF1 lesions were the most frequent of these 
cooperative events. In addition, one patient harbored two NRAS lesions (p.G13D and 
p.Q61K).
NF1 mutations in patients without clinical NF1
Two patients in our discovery cohort who were not suspected of having neurofibromatosis 
type 1 (NF1) nevertheless harbored germline NF1 mutations. One of these patients was 
heterozygous for the mutation in both the tumor and matched normal (buccal cells) with no 
loss of heterozygosity noted in the tumor. Another patient had an NF1 mutation with an 
allelic fraction of 10.1% in the germline tissue (buccal cells). The allelic fraction in the 
tumor increased to 45.3% after a copy neutral duplication at 17q. While a low allelic event 
in the germline tissue could be explained as a somatic only variant with contamination of 
tumor into normal, application of the deTIN algorithm estimated that no such contamination 
(95% CI=0-3.35%) occurred, based on the absence of copy number alteration in the normal 
tissue. This raises the possibility of somatic mosaicism, which occurs in clinical NF1 and 
often presents with subtle clinical features21. In our validation cohort, an additional six 
patients harbored NF1 mutations but only three were suspected of having clinical NF1. It is 
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not possible to determine the somatic versus germline origin of these lesions, as germline 
tissue was not available on these patients. These observations are consistent with a previous 
study indicating that JMML can be the first manifestation of NF1 in some affected infants 
and young children22.
Activated JAK/STAT corresponded with poor clinical outcome
We previously found that increased STAT5 phosphorylation in a subset of myeloid cells is a 
general feature of JMML23. The tumor suppressor LNK is encoded by SH2B3 and 
negatively regulates JAK/STAT signaling24. Mutations in SH2B3 were first reported in a 
variety of adult myeloproliferative neoplasms (MPNs) including primary myelofibrosis and 
essential thrombocythemia, as well as in isolated erythrocytosis25-27. The alterations 
included nonsense and missense mutations affecting the pleckstrin homology (PH) and/or 
the Src homology 2 (SH2) domains. Mutations in SH2B3 have also been identified in 
lymphoid malignancies including acute lymphoblastic leukemia as both germline and 
somatic events28. Two patients in the discovery cohort possessed compound heterozygous 
mutations in SH2B3 in addition to a known JMML driver mutation. Each patient had a 
nonsense mutation in both the PH domain as well as the SH2 domain (Figure 3A). While 
one patient harbored these mutations at diagnosis, the other only had detectable SH2B3 
mutations upon transformation to acute myeloid leukemia (AML). The latter patient 
relapsed with AML three years after his initial diagnosis. Protein lysates collected from 
unsorted primary mononuclear cells from these patients showed a decrease in LNK by 
immunoblot, commensurate with the allelic fraction of the patients nonsense mutations, 
respectively (Figure 3B). One additional patient without any other identifiable mutations 
was found via exome sequencing to harbor a germline SH2B3 p.E400K alteration, which is a 
non-synonymous SNP that has been previously associated with idiopathic erythrocytosis29. 
In the validation cohort, an additional four patients were found to harbor SH2B3 mutations 
for a cumulative incidence of 7.0% (7/100) (Supplementary Table 3).
We did not identify any activating JAK3 mutations in our exome discovery cohort, but 
performed resequencing with improved coverage (680X) in our validation cohort given prior 
reports12. These studies uncovered JAK3 mutations in 6 of 83 cases (7.3%). Of note, 3 of 4 
patients with JAK3 mutations at diagnosis went on to relapse. Two other patients had lesions 
detected only at relapse (allelic fractions of 8.6% and 37.4%) and presumably had subclonal 
mutations at diagnosis below the threshold of identification by our exome sequencing.
SETBP1 mutations are frequently subclonal at diagnosis
We detected a similar incidence of SETBP1 (7/100, 7.0%) mutations using deep sequencing 
as was previously reported by Sakaguchi et al12. An additional 17 patients were found to 
harbor subclonal SETBP1 mutations using ddPCR 13. Combined, subclonal and clonal 
SETBP1 mutations occurred in 24/100 patients (Supplementary Table 6). No mutations were 
found on exome sequencing in ETNK1, a gene that was recently reported to co-occur with 
SETBP1 in atypical CML30.
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Transcription Factor mutations in JMML
We identified mutations in GATA231, a transcription factor broadly involved in 
hematopoiesis. Recent work has shown that germline GATA2 mutations are responsible for 
several syndromes leading to a predisposition to myeloid malignancies and opportunistic 
infections32-34. Two patients harbored three heterozygous mutations, all of which occur in 
the regulatory zinc finger domain (ZF1). The overwhelming majority of mutations occurring 
in prior reports are in either ZF1 or ZF234-36. One of these two patients harbored both a 
germline and a somatic GATA2 mutation as previously described37. The other patient was 
found to have a somatic p.N317S variant on one allele which has been previously detected 
in patients with both MDS and AML38,39.
A heterozygous nonsense RUNX1 mutation was also found in one patient at diagnosis and in 
another at relapse, representing the first reports of haploinsufficient RUNX1 mutations in 
JMML40. Haploinsufficient missense mutations in RUNX1 have been previously reported in 
other malignancies such as MDS and SML, and are predicted to be inactivating41.
Wiskott-Aldrich syndrome mutations (WAS) in JMML
Previous reports have documented germline WAS mutations in patients suspected of having 
JMML42,43. Similarly, we detected one male patient with a germline WAS p.H180N 
mutation which has been described in several patients with Wiskott-Aldrich syndrome44. 
Interestingly, this patient also had a somatic NRAS p.G12S mutation. To the best of our 
knowledge there are no prior reports in the literature of patients with concomitant germline 
mutations in WAS and somatic mutations in Ras pathway genes.
Mutations in Epigenetic modifiers are frequent in JMML
In contrast to previous reports that emphasized the rarity of genetic mutations in epigenetic 
modifying genes in JMML45-47, we identified mutations in 14/100 patients for a combined 
incidence in our cohort of 14.0%. Components of the polycomb repressive complex 2 
(PRC2), including EZH2 (4/100, 4.0%) and ASXL1 (8/100, 8.0%) were mutated at diagnosis 
and clonally expanded in several patients at relapse (Supplementary Tables 2 and 3). 
Interestingly, all four patients with mutations in EZH2 (7q36.1) also had monosomy 7 
(Figure 2). We also found DNMT3A mutations in 3 patients, including one at the previously 
reported R882 hotspot and two other frame-shift mutations. Genome wide DNA methylation 
analysis demonstrated that four of five patients with ASXL1 mutations had a globally 
hypermethylated profile compared to those with wild type ASXL1 (Supplementary Figure 6), 
while one patient with a DNMT3A mutation had a globally hypomethylated profile 
consistent with previous reports48,49.
The spliceosome complex is implicated in JMML
A member of the spliceosome complex, ZRSR2 was mutated in one patient in our discovery 
cohort as well as two additional patients upon targeted resequencing. A pair wise analysis 
was carried out comparing RNA-seq data from one patient with a ZRSR2 mutation and 14 
patients wild type for ZRSR2. The patient with mutant ZRSR2 had significantly increased 
retention of U12-type introns compared to those with wildtype ZRSR2, consistent with prior 
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reports in adults with MDS50 (Supplementary Figure 7). These are the first reported ZRSR2 
mutations in JMML47,51,52. No mutations in SF3B1, U2AF1 or SRSF2 were found during 
our discovery phase.
Phylogenetic evolution at relapse
Focusing on patients with both diagnostic and relapsed material allowed us to plot the 
acquisition of mutations over time (Supplementary Figure 8 and Supplementary Tables 2 
and 3). All of the pathogenic mutations at diagnosis were present at relapse. However, it 
should be noted that due to the low number of mutations per sample (0.468 mutations per 
megabase), these analyses lacked the power to definitively track these clones over time. To 
further investigate the clonality of the mutations at diagnosis, we analyzed individual 
colonies obtained from diagnostic colony forming unit-granulocyte-macrophage assays 
(Supplementary Table 7). Patients UPN1420 and UPN2531 were particularly interesting 
because of the pattern of SH2B3 mutations detected. UPN2531 possessed a PTPN11 driver 
mutation along with compound heterozygous mutations in SH2B3 at diagnosis. By contrast, 
UPN1420 only acquired mutations in SH2B3 upon transformation to AML (Supplementary 
Figure 9A). More strikingly, colonies were homozygous for either the p.Q258* (19/24) or 
p.F390fs mutations (5/24). These clones were likely the result of copy number alterations 
occurring on 12q in individual cells that contained heterozygous SH2B3 mutations in a 
model of convergent evolution. Copy number variation analysis of this sample at relapse 
shows distinct duplication and loss at 12q where SH2B3 resides (Supplementary Figure 9B). 
We hypothesize that the allele containing the p.Q258* mutation duplicated in one clone 
while the p.F390fs achieved homozygosity in the other.
Clinical and Biologic Features at Diagnosis
A total of 98 of 100 children with JMML diagnosed between 2001 and 2013 at North 
American institutions were included in our analysis, with two patients excluded due to 
insufficient follow-up data (Supplementary Tables 8). Zero or 1 somatic alterations 
(pathogenic mutations or monosomy 7) were identified in 64 (65.3%) patients at diagnosis 
compared to 2 or more alterations in 34 (34.7%) (mean number of alterations = 1.32; Range 
= 0 to 4). Several clinical and biologic characteristics showed statistically significant 
differences when compared between these groups (Supplementary Table 9). A higher 
proportion of patients diagnosed with 2 or more alterations were older (p<0.001) and male 
(p=0.001). These patients also demonstrated a higher rate of monosomy 7 (p<0.001) or 
somatic NF1 mutations (p<0.001).
Somatic Alterations at Diagnosis Predicts Outcome
Using the number of somatic events at diagnosis, we evaluated differences in event free 
survival (EFS) and overall survival (OS). We initially identified a trend towards improved 
outcome in patients with 0-1 somatic alterations compared to those with 2 or more 
alterations in our 27 patient exome cohort (p= 0.12)(Supplementary Figure 10a). This was 
later validated in our independent cohort of 71 patients (p=0.0004)(Supplementary Figure 
10b). Combining both cohorts (98), patients with 0-1 somatic alterations at diagnosis had 
improved outcomes compared with patients who had 2 or more alterations (EFS HR 2.09, 
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p=0.009, OS HR 2.02 p=0.018). The 10-year EFS and OS rates according to number of 
somatic events at diagnosis were as follows (± SE): 0-1 alterations, 60.6% ±6.2% and 65.1% 
±6.0% and 2 or more alterations, 22.7% ± 7.4% and 29.0% ± 8.3% (Figures 4A and 4B; 
p=0.003 and p=0.002). Of note, log-rank tests detected statistically significant differences in 
times to both outcomes based on this predictor variable. Interestingly, EFS and OS based on 
canonical Ras pathway driver alterations including PTPN11, NF1, NRAS, KRAS and CBL 
were not statistically different from each other in our cohort (p=0.834)(Supplementary 
Figure 11). Of note, EFS for patients with double Ras pathway mutations (14%, n=7) in our 
cohort was significantly inferior compared to patients with a single Ras pathway mutation 
(62%, n=55)(p=0.017). This difference in outcome implies a dosage effect based on the 
number of Ras mutations and suggests that both compound Ras mutations have biological 
activity.
Prior studies have assigned a poorer prognostic significance to several clinical and 
laboratory characteristics in patients with JMML including; older age, male gender, lower 
platelet count, higher fetal hemoglobin, monosomy 7, PTPN11 status, and subclonal 
SETBP1 status. In univariate Cox analyses (Supplementary Table 10), characteristics that 
reached significance for EFS and OS were: age ≥24 months (HR 2.09 CI 1.20-3.62, p=0.009 
and HR 2.03, CI 1.13-3.66, p=0.018) and monosomy 7 (HR 1.24, CI 1.01-1.52, p=0.040 and 
HR 1.29, CI 1.04-1.60, p=0.019). Importantly, the most statistically significant covariate in 
this analysis was the number of somatic alterations at diagnosis (EFS HR 2.65, CI 1.27-5.54, 
p=0.01 and OS HR 3.13, CI 1.39-7.01, p=0.006). Furthermore, when modeled in a Cox 
multivariate regression, only the number of somatic alterations at diagnosis retained 
statistical significance for both EFS and OS. Two or more somatic events remained 
independently prognostic of poor outcome (HR 2.86 CI 1.35-6.05, p=0.0006 and HR 3.00, 
CI 1.27-8.40, p=0.0008) after adjusting for age, platelet count, fetal hemoglobin, and NF1 
status at diagnosis (Table 2).
We assessed the relapse incidence in patients who were treated with HSCT. Of the 79 
patients in our cohort who received HSCT and had follow-up data, 49 (62%) harbored 0-1 
alterations at diagnosis compared to 30 (38%) with 2 or more. As expected, the cumulative 
incidence of relapse from time of HSCT was significantly higher in the cohort with 2 or 
more events at diagnosis (77.7% ± 8.56) compared to those with 0-1 events (38.4% ± 8.33, 
log-rank p= 0.0002) (Supplementary Figure 12).
DISCUSSION
While previous genomic and biochemical analyses in JMML have emphasized the 
dependence on the Ras pathway for initiation of disease12, we hypothesized that additional 
pathways may be important for both disease initiation and progression. By studying patients 
with progressive disease and by optimizing the use of germline controls, the mutational 
spectrum in JMML is now expanded to include some molecules with “off the shelf” 
therapeutic implications while others will require further investigation. In addition to 
identifying another member in the Ras family of oncogenes mutated in JMML (RRAS2), we 
also uncovered additional genetic pathways contributing to leukemogenesis, including 
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upregulated JAK/STAT signaling, and epigenetic modification through the PRC2 and 
spliceosome complexes.
This report is the first to identify SH2B3 mutations in JMML. Combined with a previous 
study that uncovered missense JAK3 alterations12, these data raise the possibility of using 
JAK inhibitor therapy in the subset of patients harboring these mutations. This is also the 
first report of ZRSR2 mutations in this disease.
In contrast to chronic myelomonocytic leukemia (CMML) where epigenetic mutations are 
frequent53, previous reports in JMML have focused on the rarity of these events. However, 
14% of patients in our cohort harbored genetic alterations in epigenetic modifying genes. 
We show that ASXL1 mutations result in globally hypermethylated profiles. Patients 
exhibiting aberrant methylation would be predicted to respond to DNA hypomethylating 
agents and prior case reports support that these agents have clinical utility in JMML54. 
Currently, a phase I/II trial using 5-azacytidine in children with JMML is enrolling patients 
in Europe. Mutations in DNMT3A typically cause decreased methyltransferase activity and 
result in focal areas of CpG hypomethylation55.
Obtaining germline tissue in children was of critical importance in our study because 
approximately 25% of patients have inherited syndromes that predispose to the development 
of JMML. In addition, unlike other hematologic malignancies where one can use remission 
marrow samples for germline tissue, JMML patients rarely respond to traditional 
chemotherapy prior to transplant56. By developing innovative algorithms to identify TiN 
content with retrieval of minor differences in tumor-normal comparisons, we identified 
several variants that would have otherwise been overlooked using standard approaches. We 
showed that sources such as buccal swabs, cord blood and EBV immortalized lymphocytes 
were all suboptimal compared to bone marrow fibroblasts. While buccal samples are 
frequently “contaminated” with tumor by infiltrating leukemic cells, cord blood and EBV 
samples revealed biologic insights into this disease.
In the majority of cord blood samples, the canonical mutation was retrievable, thus revealing 
the in utero nature of leukemic initiation57,58. Of note, the mean age at diagnosis of the five 
patients who had cord blood available was 6.6 months. Interestingly, no secondary 
mutations were identified at diagnosis in any of these children, which may explain why 
younger age at diagnosis has traditionally been a more favorable clinical risk factor for 
outcome. B cells immortalized with EBV also provide insights into the range of 
hematopoietic lineages affected by JMML mutations, with many patients appearing to have 
clonal involvement of their mutations in the B cell compartment, while others only had 
myeloid cell involvement. There were insufficient patients available to determine how 
frequently this occurs.
Several mutated genes novel to JMML were identified in relapsed samples, including 
RUNX1 and JAK3. However, in contrast to most malignancies where a branching model of 
disease evolution with mutation acquisition and dropout is common59, JMML appears to 
have a unique model of progression. Specifically, mutations identified at diagnosis 
invariably persisted at relapse in all 16 patients analyzed over time. In addition, the cancer 
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cell fraction for mutations identified at diagnosis on exome sequencing approached 100%, 
implying that all mutations occurred within a single dominant clone. Single colony analysis 
in three patients with available cryopreserved cells was consistent with a linear model of the 
acquisition of additional genetic features (Supplementary Figure 9 and Supplementary 
Tables 5 and 7). When developing new therapeutic strategies for these patients, it will be 
critical to understand how secondary mutations alter the behavior of these cells in contrast to 
cells harboring only the primary lesion. Indeed, combinatorial therapies with agents that 
target the Ras pathway as well as the secondary genetic event may be necessary, as our work 
demonstrates that the clone harboring the secondary event frequently expands at disease 
progression. For example, combining a MEK inhibitor with DNA hypomethylating agents 
could prove more efficacious in the correct genetic context than monotherapy with a MEK 
inhibitor alone60,61.
Previous reports have reached different conclusions regarding the prognostic significance of 
canonical Ras pathway mutations in JMML5,6. We show that the five Ras pathway genes are 
not independently prognostic of outcome, precluding their sole use in a risk stratification 
algorithm. Consistent with our hypothesis, we found that the number of mutations at 
diagnosis, rather than the type of mutations, possesses prognostic relevance.
In conclusion, we demonstrate that patients with JMML who harbor two or more somatic 
alterations at diagnosis had a significantly worse EFS and OS compared to those with one or 
fewer events. Prior reports which identified older age, male gender, and lower platelet count 
as markers of poor outcome were likely descriptors of patients with two or more underlying 
somatic alterations. Importantly, in addition to identifying patients with aggressive disease, 
our expanded mutational spectrum will serve as a platform for studying the interactions of 
these secondary events in the context of hyperactive Ras/MAPK signaling. These studies 
will allow further interrogation of multiple molecular targets that can be exploited in patients 
predicted to have poor outcomes using conventional HSCT.
Online Methods
Patients
Twenty-nine patients diagnosed with JMML were included in the discovery cohort and had 
germline-tumor pairs evaluated by whole exome sequencing. Seven of these patients also 
had relapse samples included in the exome analysis (Supplementary Table 1). A validation 
cohort comprised of 71 distinct patients was tested for the 16 genes found to be mutated 
(including JAK3, for which we did not identify lesions on exome) during the discovery 
phase. Ninety-eight patients with confirmed JMML based on the internationally accepted 
criteria62 were included in the survival analysis. In addition to the date of diagnosis, follow-
up, and sequencing data, 12 potential clinical and laboratory prognostic factors were 
analyzed (Supplementary Tables 8). Ten of these patients had relapsed tissue included in the 
targeted resequencing. Fifty of the validation cohort samples were from patients that were 
enrolled in clinical trial AAML0122, which evaluated the safety and efficacy of a farnesyl 
transferase inhibitor as a window treatment before HSCT63. Eleven of the 81 validation 
samples were previously included in the discovery cohort. Fourteen patients from the 
combined cohorts also had RNA-seq performed. Twelve patients had genome wide DNA 
Stieglitz et al. Page 11













methylation analysis performed. Approvals for these studies were obtained from the 
University of California San Francisco (UCSF) Committee on Human Research. All 
participants/guardians provided informed consent in accordance with the Declaration of 
Helsinki.
Tissue
Germline DNA was extracted using standard methods from buccal swabs, cord blood, skin 
fibroblasts, bone marrow fibroblasts, or EBV immortalized cell lines as available. Tumor 
DNA was extracted using standard methods from bone marrow or peripheral blood 
mononuclear cells obtained at diagnosis and relapse when available. RNA was extracted 
using a TRIzol chloroform method.
Discovery
Whole exome sequencing was performed utilizing the Illumina platform as described 
previously. In brief, DNA was fragmented by sonication (Covaris Inc., Woburn, MA) to 150 
bp and further purified using Agencourt AMPure XP beads. Fifty ng of size-selected DNA 
was then ligated to specific adaptors during library preparation (Illumina TruSeq, Illumina 
Inc., San Diego, CA). Each library was made with sample-specific barcodes and quantified 
by quantitative PCR (Kapa Biosystems, Inc., Woburn, MA), and two libraries were pooled 
to a total of 500 ng for exome enrichment using the Agilent SureSelect hybrid capture kit 
(Whole Exome_v1.1; Agilent Technologies, Santa Clara, CA). Several captures were pooled 
further and sequenced in one or more lanes to a final equivalent of two exomes per lane on a 
HiSeq 2500 system (Illumina Inc., San Diego, CA).
Somatic variant, germline variant, and small deletions and insertion calling was performed 
within the Firehose environment at the Broad Institute with the previously published 
MuTect64, Haplotype65,66 and Indelocator67. In addition, we manually reviewed all 
candidate driver events using the Integrative Genome Viewer Genome-wide copy-ratio 
profiles were inferred using CAPSEG68. Read-depth at capture targets in tumor samples was 
calibrated to estimate copy-ratio using depths observed in a panel of normal genomes. We 
then segmented the copy-ratio profiles using the circular binary segmentation (CBS) 
algorithm68. Next we performed allelic copy analysis using reference and alternate counts at 
germline heterozygous SNP sites. This data allows for identification of copy neutral LOH 
events and inference of the contribution of each chromosome to observed copy profiles. We 
then combined the two data types to derive allelic copy ratio profiles (Supplementary Figure 
4).
To determine which observed somatic variants were pathogenic, we first identified events 
that had a minor allele frequency less than 0.001 in the ExAC database and were marked as 
deleterious by Mutation Assessor. Next, we enriched for mutated genes that were previously 
implicated in myeloid malignancies. Finally, we compared the mutation's variant 
classification with the expected gene function and selected inactivating mutations for tumor 
suppressors and activating mutations in regulatory domain hotspots for oncogenes as 
annotated in the COSMIC database70,71.
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To assess tumor in normal (TiN) contamination we applied deTiN (manuscript in 
preparation) using both copy number events and mutations when available. Briefly, deTiN 
estimates tumor in normal contamination (TiN) using evidence for putative somatic events 
observed in the normal (Supplementary Table 11). The contamination estimates were then 
applied to our SNV and InDel calls to recover events previously rejected because of an 
impure germline source. We were then able to ensure higher sensitivity even with non-
optimal germline samples. We observed distinct differences of tumor in normal content 
specific to each tissue type (Supplementary Figure 13). Fibroblasts from either bone marrow 
or skin (n=4) had the lowest TiN content with a mean of less than 1%. Sixty percent of the 
buccal samples (n=10) collected at the time of diagnosis were infiltrated by leukemia cells 
and had a mean TiN content of 11%, ranging from 0% to 25%. A previous study cast doubt 
on the use of EBV-immortalized cell lines as a source of germline material in JMML13. 
Consistent with this observation, EBV-transformed lymphoblasts from two of six JMML 
patients had a TiN of <1% while four others were clearly involved by the mutations in a 
clonal fashion. Similarly, cord blood (n=5) from patients contained greater than 60% TiN in 
3 samples reflecting the presence of leukemia cells at birth72.
To estimate TiN using mutations, deTiN fits the fraction of alternate reads in the normal 
sample at candidate somatic sites. When samples had fewer than three somatic single 
nucleotide variants identified with our standard mutation calling pipeline, we used alternate 
and reference allele counts at previously identified canonical events in those samples to 
build the contamination model. To construct this model, deTiN first calculates the 
probability that a given candidate mutation is a somatic or germline event over a range of 
potential TiN levels. Then we iterate over TiN levels, each time constraining the fit using 
mutations. We repeat the same process using heterozygous SNPs in regions of allelic 
imbalance and constrain the estimate using the amount of allele imbalance observed in the 
normal in relation to the tumor. We then combine each of these estimates by adding the 
likelihood curves for each.
Next we use the combined TiN estimate to keep mutation calls from variants that were 
originally rejected as germline, but are actually 1000 times more likely to be explained by 
TiN.
Validation
A customized TruSeq amplicon kit was designed utilizing the online DesignStudio pipeline 
(llumina) that targeted the entire coding regions of 16 genes (ASXL1, CBL, DNMT3A, 
EZH2, GATA2, JAK3, KRAS, NF1, NRAS, PTPN11, RRAS, RRAS2, RUNX1, SETBP1, 
SH2B3, and ZRSR2), and covered a total of 49,710 bp with 184 amplicon regions. Libraries 
prepared from DNA of each of 91 samples were indexed and subjected to 250 bp paired-end 
sequencing on Illumina MiSeq, and data of three independent MiSeq runs were combined to 
generate an average of 761,678 reads (median 383,391 reads, Supplementary Figure 14A) 
per sample. While 95.6% of total reads passed quality filtering, more than 97.4% of mapped 
reads (99.8% mapping rate) were in the targeted regions, which provided an average of 
depth coverage at 1380X across the targeted regions (Supplementary Figure 14B)
(Supplementary Table 12). Hotspots not adequately covered on the MiSeq were analyzed by 
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Sanger. The targeted sequencing data was analyzed as described previously73. In brief, after 
quality trimming, reads of each sample were aligned to the human genome reference 
sequence (GRC37/hg19), and CLC Genomic Workbench (v7.5, CLC Bio, Denmark) was 
used for mapping and variant calling. An in-house tool was then used to filter through the 
variant list, and the consequence of protein sequence changes resulting from detected DNA-
sequence changes were predicted using the functional annotation tool ANNOVAR. Only 
variants with greater than 5% allelic fraction and at least 8x depth coverage of the mutation 
allele were included as a somatic alteration, while additional detectable variants were 
reported for completeness (Supplementary Table 3).
DNA methylation analysis
Genomic DNA was bisulfite converted using the EZ DNA Methylation Kit (Zymo 
Research) and processed on Infinium HumanMethylation450 bead arrays (Illumina Inc.) 
according to the manufacturer's protocol. Probe-level signals for individual CpG sites were 
subject to both background and global dye-bias correction74. Probes that map to regions 
with known germline polymorphisms, to multiple genomic loci, or to either sex 
chromosome were filtered out. Two-way unsupervised hierarchical clustering was 
performed using Euclidean distance and Ward linkage on the 1,486 most variable CpG sites 
across the cohort, with variability ranked by standard deviation. Four subjects with clonal 
ASXL1 mutations at diagnosis were included for analysis. An additional seven patients were 
chosen as controls as they had similar mutational profiles compared to the subjects except 
they did not possess any known genetic mutations in epigenetic regulating genes 
(Supplementary Figure 6).
RNA sequencing
RNA was extracted, prepared into mRNA libraries, and sequenced by Illumina HiSeq 
resulting in paired 50nt reads, and subjected to quality control and previously described75,76. 
RNA reads were aligned using TopHat. Gene expression was quantified for transcripts 
corresponding to Gencode v12 using RPKM. Rearrangements detection was performed 
using dRanger as described previously77. Fusion detection was performed using TopHat-
Fusion.
Analysis of RNA sequencing data
For RNA-seq, paired-end sequencing was performed using the HiSeq platform with 100bp 
read length. Paired-end reads from RNA-seq were aligned to the following 4 database files 
using BWA (0.5.10) aligner: (1) the human GRCh37-lite reference sequence, (2) RefSeq, (3) 
a sequence file representing all possible combinations of non-sequential pairs in RefSeq 
exons, (4) AceView database flat file downloaded from UCSC representing transcripts 
constructed from human ESTs. The mapping results from (2) to (4) were translated to 
human reference genome coordinates. In addition, they were aligned using STAR 2.3.0 to 
the human GRCh37-lite reference sequence without annotations. A BAM file was 
constructed by selecting the best alignment among the five mappings. Poor quality mappings 
were improved using SIM4 when possible to generate the final BAM. The coverage was 
calculated using an in-house pipeline. SV detection was carried out using CICERO, a novel 
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algorithm that uses de novo assembly to identify structural variation in RNA-seq (Li et al, 
manuscript in preparation).
Digital gene expression profiling
The transcript expression levels were estimated as Fragments Per Kilobase of transcript per 
Million fragments (FPKM); gene FPKMs were computed by summing the transcript FPKMs 
for each gene using Cuffdiff278. A gene was considered “expressed” if the FPKM value >= 
0.5 based on the distribution of FPKM gene expression levels. Genes that were not 
expressed in any sample were excluded from the final data matrix for downstream analysis.
Sanger sequencing
Sanger sequencing of the discovery cohort including ASXL1 (p.Y591* and p.H630fs), 
DNMT3A (p.R882C), EZH2 (p.V674L), GATA2 (p.N317S), RRAS (p.Q87L), RRAS2 
(p.Q72L), RUNX1 (p.R349fs), SETBP1 (p.D868N, p.G870S and p.G870S), SH2B3 
(p.Q258*, p.W262*, p.F390fs, p.E400K and p.H414_splice) and ZRSR2 (p.G179E) was 
performed using the primers listed in Supplementary Table 13. All mutations were tested in 
both germline and tumor tissue in order to determine germline versus somatic acquisition 
(Supplementary Figure 15). Sequencing was carried out using Hot Start Polymerase 
(Promega) and the following PCR conditions: 95°C for 2 minutes; 35 cycles of 94°C for 45 
seconds, 60°C for 30 seconds, and 72°C for 40 seconds; and 1 cycle at 75°C for 5 minutes. 
Sequences were aligned using CLC software (CLC Bio, Aarhus, Denmark).
Single colony analysis
Mononuclear cells were isolated from fresh bone marrow or peripheral blood samples and 
resuspended in Iscove's Modified Dulbecco's Medium (IMDM) + 2% FBS. Cells were 
suspended at a concentration of 200,000 cells/ml. 154 μl of the cell suspension was added to 
a tube with the following: 1.2 ml Human Methylcellulose (R&D Systems Human 
Methylcellulose Complete Media, Cat. HSC003), 15 μl of 100X penicillin/streptomycin, 
diluted in water and IMDM to complete the tube volume to 1.54 ml. Cytokines included 
erythropoietin, granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin 3 
(IL-3), and stem cell factor (SCF). The solution was vortexed for 15 s and rested for 15 min. 
1.1 ml was plated into a 35 × 10 mm Petri dish (BD Falcon, Cat. 351008) placed into a 150 
× 15 mm Petri dish (BD Falcon, Cat. 351058) with another dish containing sterile water, and 
placed into an incubator at 37°C, 5% CO2. After 14 days, plates were removed from the 
incubator, and 2 μl of colonies (clusters of 50 cells or more) were plucked under a 
microscope at 40X magnification and resuspended in 20 μl of TE buffer. PCR amplification 
was then carried out for each of the mutations using 1 mL of the vortexed colony suspension 
and the primers listed in Supplementary Table 13.
Fibroblast cultures
Bone marrow or skin cells were cultured in Chang media (Irvine Scientific, #T105) which 
was changed every three days. Cells were split when the fibroblasts became 70% confluent 
and were harvested for DNA extraction using standard methods when the fibroblasts began 
to have a flattened morphologic appearance.
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Whole cell-extracts were prepared from previously cryopreserved samples in NP-40 lysis 
buffer supplemented with protease inhibitors. Blots were blocked with 5% BSA in TBS 
with .1% Tween 20 for 1 hour at room temperature and probed with primary anti-LNK 
(H-129, Santa Cruz) and secondary HRP-conjugated antibody (GE Healthcare) for 1 hour 
each. Protein quantification for westerns was performed using Image Lab Software (v.5.2, 
Biorad).
Statistical analyses
Data from AAML0122 were current as of June 8, 2010. Data from the remaining patients 
were current as of October 1st 2014. The number of somatic alterations at diagnosis, 
categorized as 0-1 vs. 2 or more, was the predictor variable of interest in this analysis. 
Somatic alterations were defined as a gene containing a pathogenic mutation or monosomy 
7. Clinical and biologic features were compared between these groups. The significance of 
observed differences in proportions was tested using the χ2 test (for categorical variables) or 
t test (for continuous variables), and Fisher's exact test when data were sparse. The Mann-
Whitney test was used to determine the differences in medians. The Kaplan-Meier method79 
was used to estimate probabilities of event-free survival (EFS) and overall survival (OS). 
EFS was defined as time from diagnosis to first occurrence of relapse, treatment related 
mortality, or death; OS was defined as time from diagnosis until death. EFS and OS survival 
distributions were compared according to number of somatic alterations at diagnosis using a 
two-sided log-rank test. Cox proportional hazards models62 were used to estimate the hazard 
ratio (HR) for defined groups of patients in univariate and multivariate analyses of OS and 
EFS. Relapse incidence (RI) was defined as the probability of having a relapse before time t; 
death without experiencing a relapse was considered a competing event. Cumulative 
incidence was compared using the Gray's test63. P values less than 0.05 were considered 
statistically significant. All statistical analyses were performed using STATA, version 
(STATA, College Station, TX).
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Mutations identified by exome sequencing. Twenty-nine patients who underwent whole 
exome sequencing are displayed. Each patient is presented in a single condensed column 
including mutations identified at germline, diagnostic (noted in black) and relapse (noted in 
red) timepoints. Germline mutations are presented in colors in the bottom half of the box of 
any given gene and somatic mutations in the top half. Mutations only present at relapse are 
denoted with vertical striped bars. Loss of heterozygosity in a single gene is annotated with 
a thin black rectangle surrounding the mutation. Somatic compound heterozygous mutations 
are noted with a white circle.
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Circos plot of samples with at least two mutations. Using data from whole exome and 
targeted resequencing, patients with at least two mutations are depicted. Associations 
between genomic alterations in the same patient are marked by connecting bands, with the 
width of the band proportional to the frequency of the association.
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Mutations in SH2B3 decrease expression of LNK. (a) Compound mutations in the Plekstrin 
and Src Homology 2 domains are presented for each patient found to harbor SH2B3 lesions 
on whole exome sequencing. (b) Western blot analysis from whole cell lysates using anti-
LNK and anti-B-actin antibodies. Commensurate with the allelic fraction of each mutation 
(UPN1420-Relapse, 31%, UPN2531-Diagnosis, 37%), the expression of LNK is decreased.
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Event-free and overall survival of patients stratified by the number of somatic alterations. 
Kaplan-Meier estimated (a) event-free survival (log-rank p=0.002) and (b) overall survival 
(log-rank p=0.002) according to the number of somatic alterations at diagnosis.
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Table 1
Mutations detected on WES excluding known Ras pathway genes.
Gene Mutation type RefSeq Amino acid change Nucleotide change UPN
ASXL1 Nonsense NM_015338 p.Y591* c.1773C>G UPN1420
ASXL1 Frameshift NM_015338 p.H630fs c.1888_1910del UPN1711
DNMT3A Missense NM_022552 p.R882C c.2644C>T UPN2630
EZH2 Missense NM_001203247 p.V674L c.2020G>C UPN1993
GATA2 Missense NM_001145661 p.N317S c.950A>G UPN1711
RRAS Missense NM_006270 p.Q87L c.260A>T UPN2630
RRAS2 Missense NM_012250 p.Q72L c.215A>T UPN2447
RUNX1 Frameshift NM_001001890 p.R349fs c.1047_1048insC UPN1993
SETBP1 Missense NM_015559 p.G870S c.2608G>A UPN1711
SETBP1 Missense NM_015559 p.D868N c.2602G>A UPN2301
SETBP1 Missense NM_015559 p.I871T c.2612T>C UPN1875
SETBP1 Missense NM_015559 p.G870S c.2608G>A UPN1383
SH2B3 Frameshift NM_005475 p.F390fs c.1170delC UPN1420
SH2B3 Nonsense NM_005475 p.Q258* c.772C>T UPN1420
SH2B3 Nonsense NM_005475 p.W262* c.785G>A UPN2531
SH2B3 Splice site NM_005475 p.H414_splice c.1240_splice UPN2531
SH2B3 Missense NM_005475 p.E400K c.1198G>A UPN1970
ZRSR2 Missense NM_005089 p.G179E c.536G>A UPN1646
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Table 2
Multivariate analysis of prognostic variables in JMML.
Multivariate Cox Analysis EFS from date of diagnosis OS from date of diagnosis
Somatic Alterations at Diagnosis HR 95% CI p HR 95% CI p
0-1 1 1
2 or more 2.65 1.27-5.54 0.01 3.13 1.39-7.01 0.006
Age at diagnosis (months)
<24 1 1
>24 1.62 0.82-3.21 0.167 1.55 0.73-3.28 0.25
Platelet count at diagnosis ×109
≥40 1 1
<40 1.64 0.86-3.08 0.128 2.19 1.09-4.39 0.028
Fetal hemoglobin at diagnosis
Not elevated for age 1 1
Elevated for age 1.56 0.81 -3.02 0.184 0.93 0.69-2.80 0.355
NF1 status
No 1 1
Yes 0.85 0.38 1.93 0.7 0.5 0.19-1.29 0.15
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